

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM853950

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Amneal Pharmaceuticals LLC		11/14/2023	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	JPMorgan Chase Bank, N.A., as Collateral Agent		
Street Address:	10 S. Dearborn Street		
City:	Chicago		
State/Country:	ILLINOIS		
Postal Code:	60603		
Entity Type:	National Banking Association: UNITED STATES		
PROPERTY NUMBERS Total: 33			
Property Type	Number	Word Mark	
Serial Number:	85376933	AMNEAL	
Serial Number:	78954969	AMNEAL	
Serial Number:	87947732	AMNEAL	
Serial Number:	85724888		
Serial Number:	97278717	AMNEAL PATHWAYS PATIENT ACCESS TO HEALTH	
Serial Number:	85377805	AMNEAL PHARMACEUTICALS	
Serial Number:	87437919	AXID	
Serial Number:	88167435	DOTTI	
Serial Number:	87046425	E	
Serial Number:	87834517	ELURYNG	
Serial Number:	86274536	EMVERM	
Serial Number:	87022202	FEMYNOR	
Serial Number:	87021857	LILLOW	
Serial Number:	86082154	LOMEDIA	
Serial Number:	86321948	LOPREEZA	
Serial Number:	88769420	LYLLANA	
Serial Number:	87479387	MELODETTA	
Serial Number:	90583857	MY THYROID UNIVERSE	
Serial Number:	86978765	MYRYTARY	

OP \$840.00 85376933

Property Type	Number	Word Mark
Serial Number:	87021876	NORLYDA
Serial Number:	71272349	PYRIDIDIUM
Serial Number:	76584625	REPREXAIN
Serial Number:	85586918	RYTARY
Serial Number:	88751361	RYTARY
Serial Number:	90510103	TAYSOFY
Serial Number:	87065214	THE WORLD IS OUR FAMILY
Serial Number:	87022193	TRI FEMYNOR
Serial Number:	86829218	YUVAFEM
Serial Number:	88769372	ZAFEMY
Serial Number:	90869741	LYVISPAH
Serial Number:	85215266	LIORESAL
Serial Number:	87844912	WE MAKE HEALTHY POSSIBLE
Serial Number:	73266838	DEXEDRINE

CORRESPONDENCE DATA

Fax Number: 2127514864
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.
Phone: 2129061209
Email: jess.bajada-bartlett@lw.com
Correspondent Name: LATHAM & WATKINS C/O J. BAJADA-BARTLETT
Address Line 1: 1271 Avenue of the Americas
Address Line 4: New York, NEW YORK 10020

ATTORNEY DOCKET NUMBER:	045494-0508
NAME OF SUBMITTER:	Jessica Bajada-Bartlett
SIGNATURE:	/s/ Jessica Bajada-Bartlett
DATE SIGNED:	11/16/2023

Total Attachments: 9
source=Amneal - New Trademark Security Agreement [Execution](146321801.1)#page1.tif
source=Amneal - New Trademark Security Agreement [Execution](146321801.1)#page2.tif
source=Amneal - New Trademark Security Agreement [Execution](146321801.1)#page3.tif
source=Amneal - New Trademark Security Agreement [Execution](146321801.1)#page4.tif
source=Amneal - New Trademark Security Agreement [Execution](146321801.1)#page5.tif
source=Amneal - New Trademark Security Agreement [Execution](146321801.1)#page6.tif
source=Amneal - New Trademark Security Agreement [Execution](146321801.1)#page7.tif
source=Amneal - New Trademark Security Agreement [Execution](146321801.1)#page8.tif
source=Amneal - New Trademark Security Agreement [Execution](146321801.1)#page9.tif

TRADEMARK SECURITY AGREEMENT

This TRADEMARK SECURITY AGREEMENT is dated as of November 14, 2023, by AMNEAL PHARMACEUTICALS LLC, a Delaware limited liability company and IMPAX LABORATORIES, LLC, a Delaware limited liability company (each, individually, a “Grantor” and, collectively, the “Grantors”), in favor of JPMorgan Chase Bank, N.A., in its capacity as administrative agent and collateral agent (in such capacity, the “Collateral Agent”).

W I T N E S S E T H:

WHEREAS, the Grantors are party to that certain Term Loan Guarantee and Collateral Agreement dated as of November 14, 2023 (as amended, amended and restated, supplemented, refinanced, replaced, extended or otherwise modified from time to time, the “Security Agreement”) in favor of the Collateral Agent, pursuant to which the Grantors are required to execute and deliver this Trademark Security Agreement.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Grantors hereby agree with the Collateral Agent as follows:

SECTION 1. Defined Terms. Unless otherwise defined herein, terms defined in the Security Agreement and used herein have the meanings given to them in the Security Agreement.

SECTION 2. Grant of Security Interest in Trademark Collateral. As security for the payment or performance when due (whether at stated maturity, by acceleration or otherwise), as the case may be, in full of the Secured Obligations, each Grantor hereby pledges to the Collateral Agent, its successors and permitted assigns, for the ratable benefit of the Secured Parties, and hereby grants to the Collateral Agent, its successors and permitted assigns, for the ratable benefit of the Secured Parties, a security interest in all of such Grantor’s right, title, and interest in or to any and all of the following Intellectual Property now owned or at any time hereafter acquired by such Grantor or in which such Grantor now has or at any time in the future may acquire any right, title or interest (collectively, the “Trademark Collateral”), including:

- (a) all Trademarks, including all registrations and applications therefore filed in the United States Patent and Trademark Office or any similar offices in any State of the United States (except for “intent-to-use” applications for trademark or service mark registrations filed pursuant to Section 1(b) of the Lanham Act, 15 U.S.C. § 1051, unless and until an Amendment to Allege Use or a Statement of Use under Sections 1(c) and 1(d) of the Lanham Act has been filed, to the extent that, and solely during the period for which, any assignment of an “intent-to-use” application prior to such filing would violate the Lanham Act), and all renewals thereof, including those listed on Schedule I;
- (b) all goodwill associated therewith or symbolized thereby;

- (c) all claims for, and rights to sue for, past or future infringements of any of the foregoing; and
- (d) all income, royalties, damages and payments now or hereafter due and payable with respect to any of the foregoing, including damages and payments for past or future infringement thereof.

SECTION 3. Security Agreement. The security interest granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interest granted to the Collateral Agent pursuant to the Security Agreement and the Grantors hereby acknowledge and affirm that the rights and remedies of the Collateral Agent with respect to the security interest in the Trademark Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event that any provision of this Trademark Security Agreement is deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall control.

SECTION 4. Recordation. This Trademark Security Agreement has been executed and delivered by the Grantors for the purpose of recording the grant of security interest herein with the United States Patent and Trademark Office. Each Grantor authorizes and requests that the Commissioner of Trademarks record this Trademark Security Agreement.


SECTION 5. Counterparts. This Trademark Security Agreement may be executed in one or more counterparts, each of which shall constitute an original but all of which, when taken together, shall constitute but one contract. Delivery of an executed counterpart to this Trademark Security Agreement by facsimile or other electronic transmission (e.g., "PDF" or "TIFF") shall be as effective as delivery of a manually signed original.

SECTION 6. Governing Law. THIS TRADEMARK SECURITY AGREEMENT AND ANY CLAIM, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER LOAN DOCUMENTS AND THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK (EXCEPT FOR CONFLICTS OF LAW PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION).

[Signature page follows]

IN WITNESS WHEREOF, each Grantor has caused this Trademark Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

AMNEAL PHARMACEUTICALS LLC,
as Grantor

By:  _____

Name: Anastasios Konidaris
Title: Executive Vice
President and Chief
Financial Officer

IMPAX LABORATORIES, LLC,
as Grantor

By:  _____

Name: Anastasios Konidaris
Title: Executive Vice
President and Chief
Financial Officer

Accepted and Agreed:

JPMORGAN CHASE BANK, N.A.,
as Collateral Agent

By: William R. Doolittle
Name: William R. Doolittle
Title: Executive Director


{Signature Page to Term Loan Trademark Security Agreement}

TRADEMARK
REEL: 008260 FRAME: 0090

SCHEDULE I
to
TRADEMARK SECURITY AGREEMENT

TRADEMARK REGISTRATIONS AND TRADEMARK APPLICATIONS

	Trademark/Image if any	Country Name	Application Number Filing Date	Registration Number Registration Date	Owner
1.	ADRENACLICK	US	77818149 02-Sep-2009	3797506 01-Jun-2010	Impax Laboratories, LLC
2.	AMNEAL	United States of America	85/376933 21-Jul-2011	4163617 26-Jun-2012	Amneal Pharmaceuticals LLC
3.	AMNEAL	United States of America	78/954969 18-Aug-2006	3256227 26-Jun-2007	Amneal Pharmaceuticals LLC
4.	AMNEAL and Design 	United States of America	87/947732 4-Jun-2018	5660499 22-Jan-2019	Amneal Pharmaceuticals LLC
5.	AMNEAL LOGO DESIGN 	United States of America	85/724888 10-Sep-2012	4334315 14-May-2013	Amneal Pharmaceuticals LLC
6.	AMNEAL PATHWAYS and Design 	United States of America	97/278717 22-Feb-2022	6886215 25-Oct-2022	Amneal Pharmaceuticals LLC
7.	AMNEAL PHARMACEUTICALS and Design 	United States of America	85/377805 21-Jul-2011	4197066 28-Aug-2012	Amneal Pharmaceuticals LLC
8.	AMNEALJECT	United States of America	98/025651 2-Jun-2023	Pending Intent to Use	Amneal Pharmaceuticals LLC
9.	AXID	United States of America	87/437919 5-May-2017	6315873 6-Apr-2021	Amneal Pharmaceuticals LLC
10.	BECFLO	United States of America	97/770,545 16-Nov-2022	Pending intent to use	Amneal Pharmaceuticals LLC

	Trademark/Image if any	Country Name	Application Number Filing Date	Registration Number Registration Date	Owner
11.	Q-BECFLO	United States of America	97/770,562 16-Nov-2022	Pending intent to use	Amneal Pharmaceuticals LLC
12.	BEQFLOZA	United States of America	97/770,581 27-Jan-2023	Pending intent to use	Amneal Pharmaceuticals LLC
13.	BREKIYA	US	90775004 15-Jun-2021	Pending intent to use	Amneal Pharmaceuticals LLC
14.	BRIMZY	US	97094916 27-Oct-2021	Pending intent to use	Amneal Pharmaceuticals LLC
15.	CLOQUETTE (Class 5 Pharmaceutical preparations, namely oral contraceptives)	United States of America	90/510081 4-Feb-2021	Pending intent to use	Amneal Pharmaceuticals LLC
16.	CLOQUETTE (Class 5 Transdermal contraceptives)	United States of America	98/025,701 2-Jun-2023	Pending intent to use	Amneal Pharmaceuticals LLC
17.	CONTINUON	US	90133409 24-Aug-2020	Pending intent to use	Amneal Pharmaceuticals LLC
18.	CREXONT	US	90133415 24-Aug-2020	Pending intent to use	Amneal Pharmaceuticals LLC
19.	DEXEDRINE	US	73266838 18-Jun-1980	1177791 17-Nov-1981	Amneal Pharmaceuticals LLC
20.	DOTTI	United States of America	88/167435 24-Oct-2018	5956982 7-Jan-2020	Amneal Pharmaceuticals LLC
21.	E DESIGN 	US	87046425 23-May-2016	5118599 10-Jan-2017	Amneal Pharmaceuticals LLC
22.	ELURYNG	United States of America	87/834517 14-Mar-2018	6019461 24-Mar-2020	Amneal Pharmaceuticals LLC
23.	EMPROVON	US	90133400 24-Aug-2020	Pending intent to use	Amneal Pharmaceuticals LLC

	Trademark/Image if any	Country Name	Application Number Filing Date	Registration Number Registration Date	Owner
24.	EMVERM	US	86274536 07-May-2014	4969303 31-May-2016	Amneal Pharmaceuticals LLC
25.	FEMYNOR	United States of America	87/022202 2-May-2016	5257430 1-Aug-2017	Amneal Pharmaceuticals LLC
26.	IMPAX & Design 	US	86517414 28-Jan-2015	4969799 31-May-2016	Impax Laboratories, LLC
27.	LILLOW	United States of America	87/021857 2-May-2016	5257427 1-Aug-2017	Amneal Pharmaceuticals LLC
28.	LINEAGE THERAPEUTICS	US	85890350 29-Mar-2013	4503141 25-Mar-2014	Impax Laboratories, LLC
29.	LINEAGE THERAPEUTICS (& Design) 	US	85890354 29-Mar-2013	4503142 25-Mar-2014	Impax Laboratories, LLC
30.	LOMEDIA	United States of America	86/082154 3-Oct-2013	4557571 24-Jun-2014	Amneal Pharmaceuticals LLC
31.	LOPREEZA	United States of America	86/321948 26-Jun-2014	4690032 17-Feb-2015	Amneal Pharmaceuticals LLC
32.	LYLLANA	United States of America	88/769420 22-Jan-2020	6252803 19-Jan-2021	Amneal Pharmaceuticals LLC
33.	MELODETTA	United States of America	87/479387 7-Jun-2017	5455072 24-Apr-2018	Amneal Pharmaceuticals LLC
34.	MY THYROID UNIVERSE (Class 9)	United States of America	90/583857 17-Mar-2021	6890490 01-Nov-2022	Amneal Pharmaceuticals LLC
35.	MYRYTARY	US	86978765 22-Jan-2015	4961699 17-May-2016	Amneal Pharmaceuticals LLC
36.	NORLYDA	United States of America	87/021876 2-May-2016	5312528 17-Oct-2017	Amneal Pharmaceuticals LLC

	Trademark/Image if any	Country Name	Application Number Filing Date	Registration Number Registration Date	Owner
37.	PEMRYDI RTU	United States of America	97/680,476 16-Nov-2022	Pending intent to use	Amneal Pharmaceuticals LLC
38.	PEMQUIPT	United States of America	97/680,521 16-Nov-2022	Pending intent to use	Amneal Pharmaceuticals LLC
39.	PYRIDIUM	United States of America	71/272349 13-Sep-1928	251253 1-Jan-1929	Amneal Pharmaceuticals LLC
40.	REPREXAIN	United States of America	76/584625 25-Mar-2004	2978031 26-Jul-2005	Amneal Pharmaceuticals LLC
41.	REYDAYA	US	97095051 27-Oct-2021	Pending intent to use	Amneal Pharmaceuticals LLC
42.	RYSUPEN	US	90764606 9-Jun-2021	Pending intent to use	Amneal Pharmaceuticals LLC
43.	RYTARY	US	85586918 2-Apr-2012	4724116 21-Apr-2015	Amneal Pharmaceuticals LLC
44.	RYTARY (Stylized) 	US	88751361 08-Jan-2020	6091084 30-Jun-2020	Amneal Pharmaceuticals LLC
45.	STEYON	US	90133390 24-Aug-2020	Pending intent to use	Amneal Pharmaceuticals LLC
46.	TAYSOFY	United States of America	90/510103 4-Feb-2021	6776230 28-Jun-2022	Amneal Pharmaceuticals LLC
47.	THE WORLD IS OUR FAMILY	United States of America	87/065214 8-Jun-2016	5247584 18-Jul-1027	Amneal Pharmaceuticals LLC
48.	TRI FEMYNOR	United States of America	87/022193 2-May-2016	5257429 1-Aug-2017	Amneal Pharmaceuticals LLC
49.	YUVAFEM	United States of America	86/829218 23-Nov-2015	5101795 13-Dec-2016	Amneal Pharmaceuticals LLC
50.	ZAFEMY	United States of America	88/769372 22-Jan-2020	6456756 17-Aug-2021	Amneal Pharmaceuticals LLC

	Trademark/Image if any	Country Name	Application Number Filing Date	Registration Number Registration Date	Owner
51.	LYVISPAH	United States of America	90/869,741	Pending	Amneal Pharmaceuticals LLC
52.	LIORESAL	United States of America	85/215,266 11-Jan-2011	4006164 02-Aug-2011	Amneal Pharmaceuticals LLC
53.	WE MAKE HEALTHY POSSIBLE	United States of America	87844912 22-Mar-2018	5663032 22-Jan-2019	Amneal Pharmaceuticals LLC
54.	MOST-TRUSTED AFFORDABLE MEDICINE COMPANY	United States of America	97844555 17-Mar-2023	Pending intent to use	Amneal Pharmaceuticals LLC
55.	AFFORDABLE MEDICINE COMPANY	United States of America	97844550 17-Mar-2023	Intent to use – Pending	Amneal Pharmaceuticals LLC